Gene-guided hormone therapy before prostate cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older.
- You have prostate cancer that has spread to nearby tissues or a few bones (no more than 5 spots) but not to distant organs.
- You are willing and able to have surgery to remove the prostate after the hormone therapy.
- You have not had any previous cancer treatments (except up to 28 days of certain hormone drugs).
- Your overall health is good enough to tolerate treatment and surgery, with normal blood cell counts and kidney/liver function.
- You agree to genetic testing and use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a new hormone pill called rezvilutamide to the usual treatment (hormone therapy plus surgery and targeted radiation) can better control prostate cancer that has spread to a few small spots.
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
Hear when a new Locally Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.